

Genomic Medicine and NIH

Francis S. Collins, M.D., Ph.D.

Director, National Institutes of Health

Global Leaders in Genomic Medicine

January 8, 2014



NIH: Steward of Medical and Behavioral Research for the Nation






“Science in pursuit of **fundamental knowledge** about the nature and behavior of living systems ... and the **application of that knowledge** to extend healthy life and reduce illness and disability.”





The Human Genome Project

1990–2003




The Cancer Genome Atlas
*Understanding genomics
to improve cancer care*



1000 Genomes
A Deep Catalog of Human Genetic Variation




Genetic Variants Associated with Disease Risk



Cost of Sequencing a Human Genome

September 2001–October 2013




Disorders with Known Molecular Basis



Source: Online *Mendelian Inheritance in Man*, Morbid Anatomy of the Human Genome

The Beery Twins



Alexis and Noah diagnosed with cerebral palsy (CP) at age two



Sequencing found a new genetic disease; readily treated with the addition of an amino acid to diet



A CELEBRATION OF SCIENCE

mm to futur

A CELEBRATION OF SCIENCE

CELEBRATION OF SCIENCE

A CELEBRATION OF SCIENCE

CELEBRATION OF SCIENCE

A CELEBRATION OF SCIENCE

A CELEBRATION OF SCIENCE

Undiagnosed Diseases and NIH

- Undiagnosed Diseases Program (launched 2008)
 - Patients have longstanding medical conditions that have eluded diagnosis; seen at NIH Clinical Center
 - Trans-NIH staff, led by Dr. William Gahl, has:
 - Evaluated ~3,000 medical records
 - Accepted ~700 cases
 - Determined a diagnosis in ~25%

HARD CASES: INVESTIGATING RARE & TOUGH DISEASES

Dr. William Gahl is one of the last, best hopes for people suffering from rare, debilitating, and undiagnosed medical conditions

2013
FEB 25


CBSNews.com / CBS Evening News / CBS This Morning



60 MINUTES



Disorders with Known Molecular Basis



Source: Online *Mendelian Inheritance in Man*, *Morbid Anatomy of the Human Genome*

NIH: Genomics and Drug Discovery

- Therapeutics for Rare and Neglected Diseases (TRND)
 - Collaborations with expert outside labs to speed development of new drugs for rare and neglected diseases
- Discovering New Therapeutic Uses for Existing Molecules
 - Pharma partners have made 58 compounds, biologics, and associated data available to select NIH grantees
- High tech human biochips to test for toxicity – for all 10 major organ systems
 - Partnership with DARPA; FDA





**Our laws and institutions must go
hand-in-hand with progress of the
human mind.**

Thomas Jefferson

Major Legal Decision for Genomic Medicine: U.S. Supreme Court Ruling on Patenting Human Genes

- **1997/1998:** U.S. patents result in exclusive rights for diagnostic testing to Myriad for *BRCA1* and *BRCA2*
- **2009:** AMP/ACLU lawsuit filed asserting that patents on these genes should never have been allowed
- **2013:** U.S. Supreme Court rules that genes in their natural state are not patentable



SUPREME COURT

ASSOCIATION FOR PROGRESSIVE SURGERY
v. MYRIAD

CERTIORARI TO THE UNITED STATES SUPREME COURT

No. 12-398. Argued April 15, 2013. --Decided June 13, 2013

UNITED STATES

ASSOCIATION FOR PROGRESSIVE SURGERY ET AL.

vs. MYRIAD ET AL.

The Washington Post
Supreme Court ruling says genes may not be patented

By Robert Barnes and Brady Dennis, Published: June 13



Regulatory Challenges: Preparing the Pathway to Effective Personalized Medicine

November 19, 2013: FDA announced first regulatory clearance of high-throughput DNA sequencing device

- Authorized broad clinical use of Illumina MiSeqDx
 - Allows fast, full, accurate sequencing of patient's genome
- Potential applications include:

The image shows a screenshot of a webpage. At the top is the FDA logo and the text "U.S. Food and Drug Administration". Below that is the heading "FDA NEWS RELEASE". To the left, there is a vertical list of links: "For Immediate Release", "Media Inquiries", "Consumer Information", "FDA Allowances", and "Two devices". The main content area features a banner with a collage of scientific images (DNA, cells, etc.) and the text "The NEW ENGLAND JOURNAL of MEDICINE". Below the banner is the word "Perspective" in a large, light font, with "DECEMBER 19, 2013" in red underneath. At the bottom of the banner area, the text reads "First FDA Authorization for Next-Generation Sequencer" followed by "Francis S. Collins, M.D., Ph.D., and Margaret A. Hamburg, M.D.".

Regulatory Challenges: Preparing the Pathway to Effective Personalized Medicine

- November 22, 2013: FDA warns 23andMe to discontinue marketing its Personal Genome Service until it receives clearance



Department of Health and Human Services

Nov 22, 2013

Ann Wojcicki
CEO
23andMe, Inc.
1390 Shoreline Way
Mountain View, CA 94043

Document Number: **GEN1300666**
Re: Personal Genome Service (PGS)

WARNING LETTER

Dear Ms. Wojcicki,

The Food and Drug Administration (FDA) is sending you this letter because you are marketing the 23andMe Saliva Collection Kit and Personal Genome Service (PGS) without marketing clearance or approval in violation of the Federal Food, Drug and Cosmetic Act (the FD&C Act).



FDA warns Google-backed 23andMe to halt sales of genetic tests

BY TONI CLARKE AND SHARON BEGLEY
Mon Nov 25, 2013 5:11pm EST

Critical Ethical and Policy Considerations for Genomic Medicine

- GINA (Genetic Information Nondiscrimination Act, 2008)
 - Preceded by, expands on, HIPAA (Health Insurance Portability and Accountability Act, 1996)
 - Extended by Affordable Care Act of 2010

- Sharing

- Promote
- Public

- Modern



Policy Data



FEDERAL REGISTER
The Daily Journal of the United States Government

HHS.gov
U.S. Department of Health & Human Services

Draft NIH Genomic Data Sharing Policy

News Release

A Notice by the National Institutes of Health on 09/20/2011

FOR IMMEDIATE RELEASE
July 22, 2011

HHS announces proposal to improve rules protecting human research
Changes under consideration would ensure the highest standards of protection research, while enhancing effectiveness of oversight




Embargoed until
Dec. 12, 2013 at 2 p.m.

ANTICIPATE and COMMUNICATE
Ethical Management of Incidental and Secondary Findings in the Clinical, Research, and Direct-to-Consumer Contexts

Presidential Commission
for the Study of Bioethical Issues

December 2013



Science knows no country, because knowledge belongs to humanity and is the torch which illuminates the world.

– *Louis Pasteur*



NIH...

Turning Discovery Into Health

